Pharsight

Drug Patents Expiring in 2037

1. Adlarity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679086 CORIUM Systems comprising a composite backing and methods for long term transdermal administration
May, 2037

(13 years from now)

US10300025 CORIUM Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

US10307379 CORIUM Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

US11103463 CORIUM Methods for treating alzheimer's disease with donepezil transdermal system
Jul, 2037

(13 years from now)

US10016372 CORIUM Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Jul, 2037

(13 years from now)

US9993466 CORIUM Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

US11648214 CORIUM Systems and methods for long term transdermal administration
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

ADLARITY family patents

Family Patents

2. Airduo Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

3. Akeega patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11207311 JANSSEN BIOTECH Method of treating prostate cancer
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage

AKEEGA family patents

Family Patents

4. Akynzeo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529362 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(13 years from now)

US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

5. Amzeeq patents expiration

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398641 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(13 years from now)

US10849847 JOURNEY Compositions and methods for treating rosacea and acne
Sep, 2037

(13 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's drug patent expiration?
More Information on Dosage

AMZEEQ family patents

Family Patents

6. Armonair Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

7. Atorvaliq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654106 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(13 years from now)

US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(13 years from now)

Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...

Dosage: SUSPENSION;ORAL

More Information on Dosage

ATORVALIQ family patents

Family Patents

8. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771830 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)

US10842938 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)

US10688244 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children
Dec, 2037

(13 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: Method of treating an allergic reaction using an auto-injector

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

9. Azstarys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 07, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 07 May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

Family Patents

10. Bludigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

US11499050 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 08, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 08 July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BLUDIGO family patents

Family Patents

11. Brukinsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11591340 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-871) Aug 31, 2024
New Indication(I-936) Mar 07, 2027
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
New Indication(I-874) Sep 14, 2024
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

Family Patents

12. Cabometyx patents expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
New Indication(I-854) Jan 22, 2024
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028
New Indication(I-873) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Indication(I-760) Dec 19, 2020
New Product(NP) Apr 25, 2019
New Indication(I-792) Jan 14, 2022

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

13. Calcium Gluconate In Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342813 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(13 years from now)

US10130646 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers
Jul, 2037

(13 years from now)

Drugs and Companies using CALCIUM GLUCONATE ingredient

Market Authorisation Date: 29 October, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents

Family Patents

14. Cequa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: NA

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

CEQUA family patents

Family Patents

15. Definity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(13 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

Family Patents

16. Definity Rt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(13 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY RT family patents

Family Patents

17. Dextenza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-876) Oct 07, 2024
New Indication(I-800) Jun 20, 2022
New Product(NP) Nov 30, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents

18. Drizalma Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413525 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US9839626 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US11202772 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

US10959982 SUN PHARM Duloxetine sprinkles
Apr, 2037

(12 years from now)

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 July, 2019

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

More Information on Dosage

DRIZALMA SPRINKLE family patents

Family Patents

19. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

20. Evekeo Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160772 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

US10441554 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 16 April, 2021

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

EVEKEO ODT family patents

Family Patents

21. Fintepla patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947183

(Pediatric)

UCB INC Fenfluramine compositions and methods of preparing the same
Jun, 2037

(13 years from now)

US11786487 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11406606 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US10603290 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11040018 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11759440 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
New Product(NP) Jun 25, 2023
Pediatric Exclusivity(PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Method of treating seizures in a patient by administering a liquid formulation of fenfluramine or its salts plus stiripentol thereby reducing norfenfluramine formation while increasing the fenfluramin...

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

22. Firdapse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-223) Nov 28, 2025
New Patient Population(NPP) Sep 29, 2025
New Chemical Entity Exclusivity(NCE) Nov 28, 2023

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents

23. Fleqsuvy patents expiration

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's drug patent expiration?
More Information on Dosage

FLEQSUVY family patents

Family Patents

24. Fluorescein Sodium And Benoxinate Hydrochloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10293047 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(13 years from now)

US10632197 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(13 years from now)

US10842872 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions
Nov, 2037

(13 years from now)

Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient

Market Authorisation Date: 09 March, 2020

Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE family patents

Family Patents

25. Galafold patents expiration

GALAFOLD's oppositions filed in EPO
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(12 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

26. Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

27. Gloperba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226423 SCILEX PHARMS Colchicine drug-to-drug interactions
Dec, 2037

(13 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of GLOPERBA before it's drug patent expiration?
More Information on Dosage

GLOPERBA family patents

Family Patents

28. Goprelto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Met...

Dosage: SOLUTION;NASAL

More Information on Dosage

GOPRELTO family patents

Family Patents

29. Hemady patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537585 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)

US11304961 DEXCEL Compositions comprising dexamethasone
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-271) Oct 03, 2026

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET;ORAL

More Information on Dosage

HEMADY family patents

Family Patents

30. Igalmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11839604 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)

US11786508 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with schizophrenia by sublingual or buccal adminis...

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

Family Patents

31. Ingrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

US11439629 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-440) Aug 18, 2030
New Indication(I-925) Aug 18, 2026
New Chemical Entity Exclusivity(NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

32. Inlyta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

33. Katerzia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894039 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11364230 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11484498 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10952998 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11701326 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10959991 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11471409 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Method of treating hypertension; Angina; A method of treating hypertension

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage

KATERZIA family patents

Family Patents

34. Korlym patents expiration

KORLYM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10151763 CORCEPT THERAP Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Jan, 2037

(12 years from now)

US10195214 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(13 years from now)

US10842800 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

35. Krazati patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 MIRATI THERAPS KRas G12C inhibitors
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2027
Orphan Drug Exclusivity(ODE-352) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 12 December, 2022

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

KRAZATI family patents

Family Patents

36. Lexette patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 18, 2024
New Dosage Form(NDF) May 24, 2021

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's drug patent expiration?
More Information on Dosage

LEXETTE family patents

Family Patents

37. Lonsurf patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026
New Indication(I-794) Feb 22, 2022
New Chemical Entity Exclusivity(NCE) Sep 22, 2020

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of metastatic gastric or gja in severely renally impaired patients treated with at least two lines of chemotherapy that included a fluoropyrimidine, a platinum, a taxane or irinotecan, and i...

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

38. Lumryz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11766418 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10272062 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11504347 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11839597 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10973795 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602513 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11065224 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11400065 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Jul, 2037

(13 years from now)

US11000498 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10952986 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602512 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10736866 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11052061 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11826335 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-431) May 01, 2030
New Product(NP) May 01, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate; Treatment of narcolepsy and associated disorders and symp...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

LUMRYZ family patents

Family Patents

39. Lupkynis patents expiration

LUPKYNIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

Family Patents

40. Miebo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10507132 BAUSCH AND LOMB INC Topical administration method
Jun, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 19 May, 2027

Market Authorisation Date: 18 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

MIEBO family patents

Family Patents

41. Myfembree patents expiration

MYFEMBREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
New Product(NP) May 26, 2024
M(M-289) Jan 27, 2026
New Indication(I-898) Aug 05, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

Family Patents

42. Numbrino patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933060 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10016407 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10857095 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10894012 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022
New Product(NP) Jan 10, 2023

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 10 January, 2020

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a lo...

Dosage: SOLUTION;NASAL

More Information on Dosage

NUMBRINO family patents

Family Patents

43. Nuplazid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(12 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2021

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

NCE-1 date: 29 April, 2020

Market Authorisation Date: 28 June, 2018

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

44. Nuzyra patents expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(13 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN) Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: TABLET;ORAL; POWDER;INTRAVENOUS

More Information on Dosage

NUZYRA family patents

Family Patents

45. Opfolda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857212 AMICUS THERAP US Augmented acid alpha-glucosidase for the treatment of Pompe disease
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE;ORAL

More Information on Dosage

OPFOLDA family patents

Family Patents

46. Orgovyx patents expiration

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786501 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US11583526 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US10449191 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

Family Patents

47. Otiprio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040004 ALK ABELLO Otic gel formulations for treating otitis externa
Nov, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 10, 2018
New Indication(I-770) Mar 02, 2021

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

OTIPRIO family patents

Family Patents

48. Oxbryta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

OXBRYTA family patents

Family Patents

49. Pizensy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: 13 February, 2024

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

PIZENSY family patents

Family Patents

50. Procysbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-162) Dec 22, 2024
Pediatric Exclusivity(PED) Jun 22, 2025
Orphan Drug Exclusivity(ODE) Aug 14, 2022
New Patient Population(NPP) Aug 14, 2018
M(M-216) Dec 22, 2020
Orphan Drug Exclusivity(ODE-45) Apr 30, 2020
Orphan Drug Exclusivity(ODE-97) Aug 14, 2022
New Dosage Form(NDF) Apr 30, 2016

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL; GRANULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage

PROCYSBI family patents

Family Patents

51. Pylarify patents expiration

Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PYLARIFY family patents

Family Patents

52. Qlosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867810 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(13 years from now)

US10639297 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(13 years from now)

US11129812 ORASIS PHARMS Ophthalmic pharmaceutical compositions and uses relating thereto
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 17, 2026

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 October, 2023

Treatment: Treatment of presbyopia

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

QLOSI family patents

Family Patents

53. Retevmo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112942 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172851 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10137124 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2025
Orphan Drug Exclusivity(ODE-301) May 08, 2027
Orphan Drug Exclusivity(ODE-303) May 08, 2027
Orphan Drug Exclusivity(ODE-302) May 08, 2027
Orphan Drug Exclusivity(ODE-409) Sep 21, 2029
Orphan Drug Exclusivity(ODE-412) Sep 21, 2029

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 08 May, 2024

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractor...

Dosage: CAPSULE;ORAL

More Information on Dosage

RETEVMO family patents

Family Patents

54. Reyvow patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

REYVOW family patents

Family Patents

55. Rezzayo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712459 CIDARA THERAPS Dosing regimens for treatment of fungal infections
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Generating Antibiotic Incentives Now(GAIN) Mar 22, 2033
Orphan Drug Exclusivity(ODE-426) Mar 22, 2030
New Chemical Entity Exclusivity(NCE) Mar 22, 2028

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 22 March, 2032

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

REZZAYO family patents

Family Patents

56. Rozlytrek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage

ROZLYTREK family patents

Family Patents

57. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SAXENDA family patents

Family Patents

58. Sohonos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864194 IPSEN INC Methods for treating heterotopic ossification
Jun, 2037

(13 years from now)

US11622959 IPSEN INC Methods for treating heterotopic ossification
Jun, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-439) Aug 16, 2030
New Chemical Entity Exclusivity(NCE) Aug 16, 2028

Drugs and Companies using PALOVAROTENE ingredient

NCE-1 date: 17 August, 2027

Market Authorisation Date: 16 August, 2023

Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva

Dosage: CAPSULE;ORAL

More Information on Dosage

SOHONOS family patents

Family Patents

59. Sunlenca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 22 December, 2026

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: TABLET;ORAL; SOLUTION;SUBCUTANEOUS

More Information on Dosage

SUNLENCA family patents

Family Patents

60. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195151 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(13 years from now)

US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(13 years from now)

US10512609 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

61. Sutab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033498 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(13 years from now)

US10143656 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(13 years from now)

US11382864 BRAINTREE LABS Solid oral sulfate salt formulations for cleansing a colon and methods of using same
Aug, 2037

(13 years from now)

US11638697 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 10, 2023

Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 10 November, 2020

Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy

Dosage: TABLET;ORAL

How can I launch a generic of SUTAB before it's drug patent expiration?
More Information on Dosage

SUTAB family patents

Family Patents

62. Terlivaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 14, 2027
Orphan Drug Exclusivity(ODE-406) Sep 14, 2029

Drugs and Companies using TERLIPRESSIN ACETATE ingredient

NCE-1 date: 14 September, 2026

Market Authorisation Date: 14 September, 2022

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TERLIVAZ family patents

Family Patents

63. Tirosint-sol patents expiration

TIROSINT-SOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537538 IBSA High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(12 years from now)

US11096913 IBSA High-stability packaged solutions of T4 thyroid hormone
Feb, 2037

(12 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 15 December, 2016

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of TIROSINT-SOL before it's drug patent expiration?
More Information on Dosage

TIROSINT-SOL family patents

Family Patents

64. Tlando patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559530 ANTARES PHARMA INC Oral testosterone undecanoate therapy
Nov, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE;ORAL

More Information on Dosage

TLANDO family patents

Family Patents

65. Trikafta (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(13 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517564 VERTEX PHARMS INC Methods of treatment for cystic fibrosis
Dec, 2037

(13 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-433) Apr 26, 2030
New Chemical Entity Exclusivity(NCE) Oct 21, 2024
New Product(NP) Apr 26, 2026

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 26 April, 2023

Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily e...

Dosage: GRANULES;ORAL; TABLET;ORAL

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

Family Patents

66. Vevye patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10813976 HARROW EYE Ophthalmic compositions comprising ciclosporin
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: NA

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

VEVYE family patents

Family Patents

67. Victoza patents expiration

VICTOZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-176) Apr 22, 2019
New Patient Population(NPP) Jun 17, 2022
New Indication(I-750) Aug 25, 2020
Pediatric Exclusivity(PED) Dec 17, 2022
M(M-115) Apr 06, 2015
New Chemical Entity Exclusivity(NCE) Jan 25, 2015

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

VICTOZA family patents

Family Patents

68. Vitrakvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11484535 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(12 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US11191766 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-215) Nov 26, 2025
Orphan Drug Exclusivity(ODE-220) Nov 26, 2025
Orphan Drug Exclusivity(ODE-221) Nov 26, 2025
New Chemical Entity Exclusivity(NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 26 November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusio...

Dosage: SOLUTION;ORAL

More Information on Dosage

VITRAKVI family patents

Family Patents

69. Vosevi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(13 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(13 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 18 July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

VOSEVI family patents

Family Patents

70. Xerava patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(13 years from now)

US11578044 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2023
Generating Antibiotic Incentives Now(GAIN) Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: 28 August, 2027

Market Authorisation Date: 27 August, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

XERAVA family patents

Family Patents

71. Xofluza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 24, 2023
New Indication(I-811) Oct 16, 2022

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 24 October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: Method for post-exposure prophylaxis of influenza

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage

XOFLUZA family patents

Family Patents

72. Xywav patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426373 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-361) Jul 21, 2027
New Indication(I-870) Aug 12, 2024
Orphan Drug Exclusivity(ODE-369) Aug 12, 2028
Orphan Drug Exclusivity(ODE-231) Jul 21, 2027
New Product(NP) Jul 21, 2023

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Market Authorisation Date: 21 July, 2020

Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered ...

Dosage: SOLUTION;ORAL

How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage

XYWAV family patents

Family Patents

73. Zoryve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940142 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US9907788 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US11793796 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US9884050 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US11819496 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half-life
Jun, 2037

(13 years from now)

US11129818 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half life
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2026

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 15 December, 2023

Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older; Topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older; Topical tr...

Dosage: CREAM;TOPICAL

More Information on Dosage

ZORYVE family patents

Family Patents

74. Ztalmy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2027
Orphan Drug Exclusivity(ODE-395) Jun 01, 2029

Drugs and Companies using GANAXOLONE ingredient

NCE-1 date: 01 June, 2026

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage

ZTALMY family patents

Family Patents

75. Zulresso patents expiration

Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
New Patient Population(NPP) Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ZULRESSO family patents

Family Patents

76. Zurzuvae patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11236121 BIOGEN INC Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2028

Drugs and Companies using ZURANOLONE ingredient

NCE-1 date: 01 November, 2027

Market Authorisation Date: 31 October, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ZURZUVAE family patents

Family Patents

List of large molecules

1. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10669594 REGENERON PHARMACEUTICALS, INC. Compositions and methods for detecting a biological contaminant
Feb, 2037

(12 years from now)

Ingredients: AFLIBERCEPT